Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection

[1]  Simon Tiberi,et al.  First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline , 2016, European Respiratory Journal.

[2]  S. Field,et al.  Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. , 2016, Chest.

[3]  R. Wilson,et al.  The antimicrobial susceptibility of non-tuberculous mycobacteria. , 2016, The Journal of infection.

[4]  P. Flume US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  Ming-wu Li,et al.  Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. R. Prevots,et al.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.

[7]  F. Silveira,et al.  Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  L. Kremer,et al.  In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[10]  N. Høiby,et al.  Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis , 2014, Respiratory Research.

[11]  J. Nick,et al.  Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. , 2014, Annals of the American Thoracic Society.

[12]  D. Falzon,et al.  Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies , 2014, BMJ Open.

[13]  C. Daley,et al.  In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease , 2012, Antimicrobial Agents and Chemotherapy.

[14]  H. Steel,et al.  Clofazimine: current status and future prospects. , 2012, The Journal of antimicrobial chemotherapy.

[15]  John D. Mitchell,et al.  Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Harminder Singh,et al.  Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). , 2011, Leprosy review.

[17]  E. Y. Kim,et al.  Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease , 2011, The Korean journal of internal medicine.

[18]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[19]  Jiann-Hwa Chen,et al.  High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. , 2010, International journal of antimicrobial agents.

[20]  M. Raffeld,et al.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. , 2008, American journal of respiratory and critical care medicine.

[21]  P. Sexton,et al.  Susceptibility to nontuberculous mycobacterial lung disease , 2008, European Respiratory Journal.

[22]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[23]  Mikio Oka,et al.  A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.

[24]  Yoshihiro Kobashi,et al.  The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study , 2006, Respiration.

[25]  S. Field,et al.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.

[26]  Ji‐Hyun Lee,et al.  Nontuberculous Mycobacteria , 2003 .

[27]  J. Igual,et al.  Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  R. Chaisson,et al.  Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.

[29]  J. Arbiser,et al.  Clofazimine: a review of its medical uses and mechanisms of action. , 1995, Journal of the American Academy of Dermatology.

[30]  M. Caldwell,et al.  Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. , 1993, The Pediatric infectious disease journal.

[31]  B. Dautzenberg,et al.  Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes. , 1991, Tubercle.

[32]  J. Garrelts,et al.  Clofazimine: A Review of its Use in Leprosy and Mycobacterium Avium Complex Infection , 1991, DICP : the annals of pharmacotherapy.

[33]  Horsburgh Cr,et al.  The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). , 1989 .

[34]  R. Selik,et al.  The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). , 1989, The American review of respiratory disease.

[35]  D. Snider,et al.  The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. , 1987, The American review of respiratory disease.

[36]  A. Fauci,et al.  Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. , 1987, The Journal of infectious diseases.

[37]  P. Stradling,et al.  Potentially serious side-effects of high-dose twice-weekly rifampicin* , 1971, Postgraduate medical journal.

[38]  P. Stradling,et al.  Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin , 1971, British medical journal.